Based on data released to date, clinicians contacted by BioCentury say the reductions in HbA1c seen with three sodium-coupled glucose co-transporter 2 (SGLT2) inhibitors - dapagliflozin, canagliflozin and ASP1941 - are similar. It is too early to compare LX4211, for which only four-week data are available. (A) Treatment-experienced and treatment-naïve patients; (B) Subset of treatment-naïve patients; (C) Body weight was dose-dependently decreased by up